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Ablative techniques provide an effective 
tool for local treatment of liver tumors. 
Radiofrequency ablation is the most 
frequently used local method, whereas 
electroporation-based treatments are 
being explored as possible alternatives. 
US imaging is mostly used for the 
identification of the electrode placement 
according to the treatment plan and US 
specific changes are detected for 
identification of adequate tumor coverage. 
Treatment monitoring and understanding 
the imaging findings to predict the tumor 
response to ECT are important.
The effect after ECT is slow. We observed 
tumor response in three phases after ECT: 
Immediate effects, Intermediate effects 
after a few days and late effects. 
We observed immediate effects with US, 
the changes in the ablation zone were 
followed to identify whether they appear 
in the entire treated tumor, therefore 
indicating an effective electroporation of 
the tumor. 
Intermediate and late effects can be 
evaluated with US, CT or MRI.
Morphologic methods such as the 
Response Evaluation Criteria in Solid 
Tumors (RECIST 1.1) are considered the 
gold standard for response assessment 
in the management of cancer. However 
conventional morphologic methods 
are confronting limitations in response 
assessment (1). 
All local treatments attempt to induce 
necrosis of the tumor, which may delay 
tumor shrinkage during the early post-
treatment period. Given these limitations 
of morphologic response criteria, the 
American Association for the Study of 
Liver Disease (AASLD) proposed the 
modified RECIST (mRECIST) criteria, 
which conceptualized viable tumor 
measurements (2). mRECIST had better 
overall response rate than conventional 
morphologic criteria such as RECIST 1.1 
(3) and a better correlation with survival. 
Diffusion-weighted MRI (DWI) is unique 
among imaging technique, although many 
studies have confirmed the usefulness 
of DWI and its diagnostic role in cancer 
imaging. A significant and growing volume 
of data are now gathering to support its 
use for tumour response assessment 
(4). Restriction in the diffusion of water 
molecules is directly proportional to 
the degree of cellularity of the tissue. 
In general, an increase in ADC value in 
response to treatment has been shown to 
be associated with better outcome (5,6).
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